Genois Biotech Secures Hundreds of Millions in Series C+ Financing to Accelerate Leadership in Precision Pathogen Diagnostics

Recently, Hangzhou Matridx Biotechnology Co., Ltd. (hereinafter referred to as “Matridx Biotechnology”), a pioneer in innovative molecular diagnostics for infectious pathogens, has completed a C+ round of financing amounting to hundreds of millions of RMB, accelerating its lead in the field of precision medicine for pathogenic microorganisms. The investors in this round includeCo-Teck Fund, Hangzhou Yuhang Financial Holdings Group Co., Ltd. and other industrial investors. This round of financing will be used for the research and development of the product pipeline, registration of medical device products, and the implementation of commercialization strategies.

Driven by multifaceted factors such as global climate change, urbanization, population aging, and rapid population mobility, novel and emerging pathogens have continued to arise in the post-pandemic era. Concurrently, the irrational use of antibiotics has become increasingly severe. Infectious diseases caused by pathogenic microorganisms have emerged as the most critical public health threat worldwide, exerting a significant impact on both social and economic development. Over the past five years, practical experience has demonstrated that next-generation molecular diagnostic technologies, represented by gene sequencing, offer significant advantages in terms of comprehensive detection, sensitivity, specificity, and timeliness. These technologies have overcome the limitations and technical shortcomings of traditional microbiological testing. They not only enable surveillance of novel and emerging infectious diseases but also better meet the public’s health needs, thereby powerfully driving the diagnosis and treatment of global infectious diseases into a new era of precision medicine.

As a pioneer in the innovation of molecular diagnostic technologies for infectious pathogens in China, Matridx Biotechnology has adhered to its mission of “Innovating to Test the Future” and its vision of “ensuring that every infected patient receives precise diagnosis and treatment at the earliest possible stage” since its establishment in 2019. Leveraging two cutting-edge technological platforms—next-generation sequencing (NGS) and gene editing (CRISPR/Cas)—the company has independently developed a globally leading suite of automated detection instruments, diagnostic reagents, and bioinformatics analysis platforms, obtaining multiple medical device registration certificates. In doing so, Matridx Biotechnology has constructed a comprehensive, scenario-based innovative molecular diagnostic solution that covers critical and complex refractory infections, moderate infections, and common infections.

Since 2020, Matridx Biotechnology has pioneered the first one-stop, fully automated mNGS product solution in China. To date, nearly 100 units have been deployed at the Chinese Center for Disease Control and Prevention (China CDC) and local CDCs at various levels. The company has also expanded the application of pathogen NGS technology from third-party laboratories to hospitals, bringing pathogen NGS testing into “zero” distance from patients. Relying on its automated precision testing products and a stringent quality management system, Matridx Biotechnology has consistently achieved outstanding results for multiple consecutive years in external quality assessment programs—including metagenomic high-throughput sequencing—organized by the National Center for Clinical Laboratories under the National Health Commission. The company has yielded fruitful research outcomes, having published nearly 30 high-impact SCI papers, filed 19 invention patent applications, obtained 35 patented rights, and secured nearly 10 software copyrights.

Currently, Matridx Biotechnology has been rated asNational-Level “Little Giant” Enterprise Specializing in Refined, Specialized, and Innovative Products; National High-Tech Enterprise; Quasi-Unicorn Enterprise of Yuhang District, Hangzhou; Zhejiang Provincial High-Tech Enterprise R&D Center, selected by KPMG China“Top 50 Biotech Innovation Companies”，CB insights“China’s Most Promising Molecular Diagnostics Company”etc.

Dr. Wang Jun, Founder and CEO of Matridx BiotechnologyWe are deeply honored to have earned the recognition and trust of the investors in this funding round. Over the five years since our establishment, we have remained true to our original mission, adhering to independent research and development while focusing on addressing our clients’ pressures and challenges. Regardless of changes in the external macroeconomic environment, we have been committed to leveraging innovative technologies and products to make the diagnosis of infectious diseases more precise, rapid, and intelligent. Moving forward, we will further accelerate the R&D of our product pipeline and shorten the regulatory approval cycle, ensuring that patients with infectious diseases receive precise diagnosis and treatment at the earliest possible stage.

Mr. Chen Guojian, Vice Chairman and General Manager of Hangzhou Yuhang Financial Holdings Group Co., Ltd.stated that precision diagnosis and treatment of infectious diseases represent a major trend in medical development, and that biopharmaceuticals are one of the five key ecological industrial clusters Yuhang District is striving to build. Over the past few years, we have witnessed Matridx Biotechnology rapidly evolve from a startup into a national-level “Specialized, Refined, Differential, and Innovative” (SRDI) Little Giant enterprise. Under the leadership of an outstanding management team, the company has effectively driven industry transformation through its independently developed innovative technologies and products. We are confident in Matridx Biotechnology’s future development and will fully support its high-quality growth, enabling it to lead the industry and create greater value for society.

Mr. Qiao Yunsheng, General Manager of Co-Teck Fundstated that in the post-pandemic era, the pain points in precision diagnosis and treatment of infectious diseases have become increasingly prominent, revealing vast market potential. As a pioneer in precision medicine for infectious diseases, Matridx Biotechnology has demonstrated courage in innovation and established an excellent portfolio of diversified product solutions, consistently driving industry development. We highly recognize Matridx’s leading position in the industry and will fully support the company’s product R&D and manufacturing, aiming to accelerate its growth in the next phase.

Hangzhou Matridx Biotechnology Co., Ltd. is a national-level “Little Giant” enterprise specializing in specialized, refined, distinctive, and innovative products, with a focus on molecular diagnostics for infectious diseases. The company was co-founded by Dr. Wang Jun, a founding team member of Berry Genomics (SZ: 000710), and Mr. Zhong Jie, former head of the strategic investment division at Dian Diagnostics (SZ: 300244) and partner at the Zhejiang Grand Health Industry Fund. Leveraging high-throughput sequencing (NGS) and gene editing (CRISPR/Cas) as its core technological platforms, Matridx integrates cutting-edge technologies such as genetic testing, big data analytics, and artificial intelligence to deliver comprehensive, scenario-based innovative molecular diagnostic solutions for the surveillance of emerging and re-emerging infectious diseases and precision medicine in various infectious disease contexts.

Hangzhou Yuhang Financial Holdings Group Co., Ltd. was established in October 2022, with a registered capital of RMB 10 billion. By the end of 2022, its total assets amounted to RMB 88.005 billion. The Group focuses primarily on capital operations as its core business, centering on five major industrial clusters: “capital operations + financial services + talent services + digital information + asset management.” Through market-oriented operations, it aims to enhance its leadership in industry incubation, improve the allocation and operational efficiency of state-owned capital, build high-end platforms for talent and digital information services, and strengthen and expand state-owned capital. The Group’s government-guided industrial funds have a total size of RMB 9.8 billion, with subordinate funds reaching a total scale of RMB 54.55 billion. It has cumulatively invested in 806 projects, with a total investment amounting to RMB 19.06 billion.

Co-Teck Fund is a private equity investment institution that combines state-owned holding with a market-oriented team. Operating under the model of “government guidance + market logic + professional management,” the Fund adheres to the principles of value investing and prudent investment. It aims to drive innovation-led technological advancement, facilitate industrial structure upgrading, and maximize fund efficacy, with a focus on supporting industries such as high-end manufacturing, the “Three New” economy (new technologies, new industries, and new business models), biotechnology, and new energy.